EUVIMEDEUVIMED entdecken
Crossref

Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies

Valentin Maisons, Anna Duval, Laurent Mesnard, Marie Frimat, Fadi Fakhouri, Steven Grangé, Aude Servais, Claire Cartery, Laurent Fauchier, Paul Coppo, Dimitri Titeca-Beauport, Nicolas Fage und 18 weitere

Kidney International · 2024

DOI: 10.1016/j.kint.2024.02.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2024. Verfasst von Valentin Maisons und 29 weiteren Autor:innen. Beteiligte Einrichtung: Service de Néphrologie, CHU de Tours, Tours, France; U1246, INSERM, SPHERE, Université de Tours, Université de Nantes, Tours, Nantes, France. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombotic microangiopathies (TMA) are usually associated with hematological features (RH-TMA). The epidemiology of TMA limited to kidneys (RL-TMA) is unclear Therefore, patients with TMA and native kidney biopsies were identified during 2009-2022 in 20 French hospitals and results evaluated. RL-TMA was present in 341/757 (45%) patients and associated with lower creatinine levels (median 184 vs 346 μmol/L) than RH-TMA. RL-TMA resulted from virtually all identified causes, more frequently from anti-VEGF treatment and hematological malignancies but less frequently from shigatoxin-associated hemolytic uremic syndrome (HUS), systemic sclerosis, gemcitabine and bacterial infection, and even less frequently when three or more causes/triggers were combined (RL-TMA: 5%; RH-TMA: 12%). RL-TMA was associated with significantly lower major cardiovascular events (10% vs 20%), kidney replacement therapy (23% vs 43%) and death (12% vs 20%) than RH-TMA during follow-up (median 28 months). Atypical HUS (aHUS) was found in 326 patients (RL-TMA: 43%, RH-TMA: 44%). Among the 69 patients with proven complement-mediated aHUS, eculizumab (anti-C5 therapy) was used in 43 (62%) (RL-TMA: 35%; RH-TMA: 71%). Among the 257 other patients with aHUS, including 51% with RL-TMA, eculizumab was used in 29 but with unclear effects of this treatment. Thus, RL-TMA represents a very high proportion of patients with TMA and results from virtually all known causes of TMA and includes 25% of patients with complement-mediated aHUS. Adverse outcomes of RL-TMA are lower compared to RH-TMA but remain significant. Anti-C5 therapy was rarely used in RL-TMA, even in proven complement-mediated aHUS, and its effects remain to be assessed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesAtypical Hemolytic Uremic SyndromeAdultHumansKidneyComplement System ProteinsKidney Function Tests

Stichwörter der Autor:innen

biopsyepidemiologykidneymalignant hypertensionmonoclonal gammopathythrombotic microangiopathies

Substanzen

Complement System Proteins

Autor:innen und Institutionen

  • Service de Néphrologie, CHU de Tours, Tours, France; U1246, INSERM, SPHERE, Université de Tours, Université de Nantes, Tours, Nantes, France.
  • Service de Néphrologie, CHU de Strasbourg, Strasbourg, France.
  • Service de Néphrologie, APHP Hopital Tenon, Paris, France.
  • Service de Néphrologie, CHU de Lille, Lille, France.
  • Service de Néphrologie, CHU Vaudois, Lausanne, Switzerland.
  • Service de Néphrologie, CHU de Rouen, Rouen, France.

Zitieren

APA

Maisons, V., Duval, A., Mesnard, L., Frimat, M., Fakhouri, F., Grangé, S., Servais, A., Cartery, C., Fauchier, L., Coppo, P., Titeca-Beauport, D., Fage, N., Delmas, Y., Quérard, A. H., Seret, G., Bobot, M., Le Quintrec, M., Ville, S., von Tokarski, F., …, & MATRIX Consortium Group (2024). Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies. Kidney International. https://doi.org/10.1016/j.kint.2024.02.014

Vancouver

Maisons V, Duval A, Mesnard L, Frimat M, Fakhouri F, Grangé S, et al. Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies. Kidney International. 2024. doi:10.1016/j.kint.2024.02.014

BibTeX
@article{Maisons2024,
  author = {Maisons, Valentin and Duval, Anna and Mesnard, Laurent and Frimat, Marie and Fakhouri, Fadi and Grangé, Steven and Servais, Aude and Cartery, Claire and Fauchier, Laurent and Coppo, Paul and Titeca-Beauport, Dimitri and Fage, Nicolas and Delmas, Yahsou and Quérard, Anne-Hélène and Seret, Guillaume and Bobot, Mickaël and Le Quintrec, Moglie and Ville, Simon and von Tokarski, Florent and Chauvet, Sophie and Wynckel, Alain and Martins, Manon and Schurder, Juliet and Barbet, Christelle and Sautenet, Bénédicte and Gatault, Philippe and Caillard, Sophie and Vuiblet, Vincent and Halimi, Jean-Michel and MATRIX Consortium Group, MATRIX Consortium Group},
  title = {Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies},
  journal = {Kidney International},
  year = {2024},
  doi = {10.1016/j.kint.2024.02.014}
}
Kostenlos starten →